東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Valuations of early-stage companies ...

SpringerLink (Online service)

Linked to FindBook

Google Book

Amazon

博客來

Valuations of early-stage companies and disruptive technologies = how to value life science, cybersecurity and ICT start-ups, and their technologies /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Valuations of early-stage companies and disruptive technologies/ by Tiran Rothman.
Reminder of title:	how to value life science, cybersecurity and ICT start-ups, and their technologies /
Author:	Rothman, Tiran.
Published:	Cham :Springer International Publishing : : 2020.,
Description:	xii, 219 p. :ill., digital ;24 cm.
[NT 15003449]:	Part I. A Short Overview of Valuations -- Chapter 1. Introduction -- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques -- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances -- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations -- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options -- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations -- Chapter 5. Introduction to Behavioral Finance -- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations -- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream? -- Part IV. An Introduction to Valuations in R&D-Intensive Industries -- Chapter 8. The Pharmaceutical Sector -- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing -- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors -- Part V. Actual Valuations -- Chapter 11. Company A: Pharmaceutical / New Compounds -- Chapter 12. Company B: Pharmaceutical / Biologies -- Chapter 13. Company C: Cybersecurity -- Chapter 14. Company D: Renewable Energy -- Chapter 15. Conclusion.
Contained By:	Springer Nature eBook
Subject:	Capital investments. -
Online resource:	https://doi.org/10.1007/978-3-030-38847-8
ISBN:	9783030388478

Valuations of early-stage companies and disruptive technologies = how to value life science, cybersecurity and ICT start-ups, and their technologies /
Rothman, Tiran.

Valuations of early-stage companies and disruptive technologieshow to value life science, cybersecurity and ICT start-ups, and their technologies /[electronic resource] :by Tiran Rothman. - Cham :Springer International Publishing :2020. - xii, 219 p. :ill., digital ;24 cm.

Part I. A Short Overview of Valuations -- Chapter 1. Introduction -- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques -- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances -- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations -- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options -- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations -- Chapter 5. Introduction to Behavioral Finance -- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations -- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream? -- Part IV. An Introduction to Valuations in R&D-Intensive Industries -- Chapter 8. The Pharmaceutical Sector -- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing -- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors -- Part V. Actual Valuations -- Chapter 11. Company A: Pharmaceutical / New Compounds -- Chapter 12. Company B: Pharmaceutical / Biologies -- Chapter 13. Company C: Cybersecurity -- Chapter 14. Company D: Renewable Energy -- Chapter 15. Conclusion.

This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration.

ISBN: 9783030388478

Standard No.: 10.1007/978-3-030-38847-8doiSubjects--Topical Terms:

646733
Capital investments.

LC Class. No.: HG4028.C4 / R68 2020

Dewey Class. No.: 658.15

Valuations of early-stage companies and disruptive technologies = how to value life science, cybersecurity and ICT start-ups, and their technologies /
LDR:03631nmm a2200325 a 4500 001 2257076
003 DE-He213
005 20210303145137.0
006 m d
007 cr nn 008maaau
008 220420s2020 sz s 0 eng d
020 $a 9783030388478 $q (electronic bk.)
020 $a 9783030388461 $q (paper)
024 7 $a 10.1007/978-3-030-38847-8 $2 doi
035 $a 978-3-030-38847-8
040 $a GP $c GP
041 0 $a eng
050 4 $a HG4028.C4 $b R68 2020
072 7 $a KFFM $2 bicssc
072 7 $a BUS036000 $2 bisacsh
072 7 $a KFFM $2 thema
082 0 4 $a 658.15 $2 23
090 $a HG4028.C4 $b R846 2020
100 1 $a Rothman, Tiran. $3 3527931
245 1 0 $a Valuations of early-stage companies and disruptive technologies $h [electronic resource] : $b how to value life science, cybersecurity and ICT start-ups, and their technologies / $c by Tiran Rothman.
260 $a Cham : $b Springer International Publishing : $b Imprint: Palgrave Macmillan, $c 2020.
300 $a xii, 219 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part I. A Short Overview of Valuations -- Chapter 1. Introduction -- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques -- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances -- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations -- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options -- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations -- Chapter 5. Introduction to Behavioral Finance -- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations -- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream? -- Part IV. An Introduction to Valuations in R&D-Intensive Industries -- Chapter 8. The Pharmaceutical Sector -- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing -- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors -- Part V. Actual Valuations -- Chapter 11. Company A: Pharmaceutical / New Compounds -- Chapter 12. Company B: Pharmaceutical / Biologies -- Chapter 13. Company C: Cybersecurity -- Chapter 14. Company D: Renewable Energy -- Chapter 15. Conclusion.
520 $a This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration.
650 0 $a Capital investments. $3 646733
650 0 $a Risk management. $3 540477
650 0 $a New business enterprises. $3 600789
650 0 $a Management. $3 516664
650 0 $a Industrial management. $3 529072
650 1 4 $a Investment Appraisal. $3 2191345
650 2 4 $a Risk Management. $3 608953
650 2 4 $a Start-Ups/Venture Capital. $3 2194714
650 2 4 $a Innovation/Technology Management. $3 1565353
650 2 4 $a Cybercrime. $3 2195714
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-38847-8
950 $a History (SpringerNature-41172)